The interim CFO appointment is a temporary measure; monitor for search for a permanent CFO and any further executive departures. The CAO departure is not a red flag alone, but the lack of a permanent CFO may indicate organizational instability typical of a micro-cap biotech.
ATRA drugs
ATRA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $11.17entry
- T+1 · 5mo ago +2.78%α +2.00% · $11.48
- T+5 · 4mo ago −2.60%α −3.98% · $10.88
- T+20 · 4mo ago −29.27%α −29.00% · $7.90
- T+60 · 8w ago −20.05%α −24.44% · $8.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atara Biotherapeutics disclosed the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO via a consulting agreement with Charles River CFO, Inc. The filing is a routine officer change and carries no material financial information.
Key Facts
- Chief Accounting Officer Yanina Grant-Huerta notified of employment end effective July 17, 2026.
- Kevin G. Sarney appointed interim CFO, principal financial officer, and principal accounting officer on June 26, 2026.
- Sarney, age 61, is a CPA with 25+ years of life science finance experience, serving via a consulting agreement with Charles River CFO, Inc. at an hourly rate.
- No compensation directly to Sarney; consulting agreement can be terminated with 30 days' notice.
- No family relationships or related-party transactions between Sarney and the company.
Financial Impact
No direct financial impact; hourly consulting fees are not disclosed.
Risk Factors
- Prolonged interim CFO arrangement could signal difficulty attracting permanent finance leadership.
- Further executive departures or financial control weaknesses may emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-285498 |
| Document: 0001193125-26-285498-index-headers.html | 0001193125-26-285498 |
| Document: 0001193125-26-285498-index.html | 0001193125-26-285498 |
| Document: 0001193125-26-285498.txt | 0001193125-26-285498 |
Track record
11 reports on ATRA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Viewing Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
- Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- May 7, 202627w ago Insider Cluster Mixed 5/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
- Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
- Mar 12, 202635w ago 8-K Neutral 5/10 Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
- Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers